fda glp-1 warning letters news FEDS CRACK DOWN ON TELEHEALTH COMPANIES SELLING GLP-1s: The U.S. Food and Drug Administration is cracking down on telehealth companies for making “false and misleading” claims about compounded versions of popular weight FDA issued 30 warning letters

A company proposes TABA as part of its overall cost-based maximum which must be built into proposals, rather than requested separately

doi: 10.1007/s11154-023-09839-9 105 WangK.DuanF.SunT.ZhangY.LuL

This activates multiple signaling pathways including protein kinase A/signal transducer and activator of transcription, phosphoinositide 3-kinases/protein kinase B, mitogen-activated protein kinase, and nuclear factor kappa B, and may exert anti-inflammatory effects in the liver and beyond

The timeline does not support this mechanism

They are very fun to programme

When compared with time periods in which other second-line antidiabetic medications were used, semaglutide and liraglutide use periods were also associated with a significantly better outcome